-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
iTeos Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2019 to Q3 2024.
- iTeos Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$48.8M, a 12.8% decline year-over-year.
- iTeos Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$150M, a 61% decline year-over-year.
- iTeos Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$151M, a 220% decline from 2022.
- iTeos Therapeutics, Inc. annual Operating Income (Loss) for 2022 was $126M, a 48.4% decline from 2021.
- iTeos Therapeutics, Inc. annual Operating Income (Loss) for 2021 was $245M.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)